Several randomized phase III trials revealed that in patients with NSCLC whose disease has progressed while on platinum‐based chemotherapy, treatment with programmed cell death‐1 (PD‐1), or programmed cell death‐ligand‐1 (PD‐L1) blockade improved overall survival (OS) compared with standard chemotherapy.2, 3, 4, 5. The gene discussed is CD274; the disease is non-small cell lung carcinoma.